Expanding Medicare’s Rx Abuse Controls Beyond Opioids Is Premature, Diverse Groups Tell CMS
This article was originally published in The Pink Sheet Daily
Executive Summary
Commenting on the draft “call letter” for the 2014 Part D plan year, associations representing drug manufacturers, pharmacists and physicians say CMS should first review issues such as how the protocols for the opioids are working and differences between opioids and other classes of drugs.